Strepsils Max Pro Lozenge Drug Interactions

Flurbiprofen should be avoided in combination with: Other NSAIDs including cyclooxygenase-2 selective inhibitors: Avoid concomitant use of two or more NSAIDs as this may increase the risk of adverse effects (esp. gastrointestinal adverse events such as ulcers and bleeding), (see Precautions).
Acetylsalicylic acid (low dose): Unless low-dose aspirin (not above 75 mg daily) has been advised by a doctor, as this may increase the risk of adverse reactions (see Precautions).
Flurbiprofen should be used with caution in combination with: Anticoagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see Precautions).
Anti-platelet Agents: Increased risk of gastrointestinal ulceration or bleeding (see Precautions).
Antihypertensive drugs (Diuretics, ACE inhibitors, angiotensin-II-antagonists): NSAIDs may reduce the effect of diuretics and other antihypertensive drugs may enhance nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with compromised renal function (Patients should be adequately hydrated).
Alcohol: May increase the risk of adverse reactions, especially of bleeding in the gastrointestinal tract.
Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels - adequate control and, if necessary, dose adjustment is recommended.
Ciclosporin: Increased risk of nephrotoxicity.
Corticosteroids: May increase the risk of adverse reactions, especially of the gastrointestinal tract (see Contraindications).
Lithium: May increase serum levels of lithium - adequate control and, if necessary, dose adjustment is recommended.
Methotrexate: The administration of NSAIDs within 24 hours before or after administration of methotrexate may lead to elevated concentrations of methotrexate and an increase in its toxic effect.
Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.
Oral antidiabetics: Alteration of blood glucose levels reported (increased check rate recommended).
Phenytoin: May increase serum levels of phenytoin - adequate control and, if necessary, dose adjustment is recommended.
Potassium-sparing diuretics: Concomitant use may cause hyperkalaemia.
Probenecid, Sulfinpyrazone: Medicinal products that contain probenecid or sulfinpyrazone may delay the excretion of flurbiprofen.
Quinolone Antibiotics: Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.
Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal ulceration or bleeding (see Precautions).
Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus.
Zidovudine: Increased risk of hematological toxicity when NSAIDs are given with zidovudine.
No studies so far have revealed any interactions between flurbiprofen and tolbutamide or antacids.